Abstract
As mentioned in Sect. 1.3, sequential statistical methods received little attention from the biomedical community until the early termination of the Beta-Blocker Heart Attack Trial (BHAT) in 1981. In Sects. 6.2 and 6.3, we describe the design details, interim analyses, and final report of BHAT. As the primary endpoint of BHAT was survival following at least one heart attack, we give an overview of survival analysis in Sect. 6.1. However, because of the sequential nature of interim analyses, traditional survival analysis methodology reviewed in Sect. 6.1 has to be extended to the sequential setting.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Andersen PK, Borgan Ø, Gill RD, Keiding N (1993) Statistical models based on counting processes. Springer Series in Statistics, Springer-Verlag, New York, DOI 10.1007/978-1-4612-4348-9
Anscombe F (1952) Large-sample theory of sequential estimation. Math Proc Cambridge Philosoph Soc 48(04):600–607
Armitage P (1960) Sequential medical trials. Charles C. Thomas, Springfield, Ill
Armitage P, McPherson CK, Rowe BC (1969) Repeated significance tests on accumulating data. J Roy Statist Soc Ser A 132:235–244
Azriel D (2012) Optimal sequential designs in phase I studies. Comput Stat Data Anal To appear
Babb J, Rogatko A, Zacks S (1998) Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 17(10):1103–1120
Barnard GA (1959) Control charts and stochastic processes (with discussion). J Roy Statist Soc Ser B 21:239–271
Bartroff J, Lai TL (2008a) Efficient adaptive designs with mid-course sample size adjustment in clinical trials. Stat Med 27(10):1593–1611, DOI 10.1002/sim.3201
Bartroff J, Lai TL (2008b) Generalized likelihood ratio statistics and uncertainty adjustments in efficient adaptive design of clinical trials. Sequent Anal 27(3):254–276
Bartroff J, Lai TL (2010) Approximate dynamic programming and its applications to the design of phase I cancer trials. Statist Sci 25:245–257
Bartroff J, Lai TL (2011) Incorporating individual and collective ethics into phase I cancer trial designs. Biometrics 67(2):596–603, DOI 10.1111/j.1541-0420.2010.01471.x
Bauer P (1989) Multistage testing with adaptive designs. Biometrie und Informatik in Medizin und Biologie 20:130–148, with discussion
Bauer P, Köhne K (1994) Evaluation of experiments with adaptive interim analyses. Biometrics 50(4):1029–1041, DOI 10.2307/2533441
Bayard DS (1991) A forward method for optimal stochastic nonlinear and adaptive control. IEEE Trans Automat Contrl 36(9):1046–1053, DOI 10.1109/9.83535
Beal, S.L. and Sheiner, L.B., eds. (1992), NONMEM User.s Guide, University of California, San Francisco, NONMEM Project Group.
Berry SM, Carlin BP, Lee JJ, Müller P (2011) Bayesian adaptive methods for clinical trials. Chapman & Hall/CRC biostatistics series, vol 38. CRC, Boca Raton
Bertsekas DP (2007) Dynamic programming and optimal control, vol II, 3rd edn. Athena Scientific Belmont, Masssachusetts
Beta-Blocker Heart Attack Trial Research Group (1982) A randomized trial of propranolol in patients with acute myocardial infarction: 1. mortality results. J Am Med Assoc 247(12):1707–1714
Beta-Blocker Heart Attack Trial Research Group (1984) Beta-blocker heart attack trial: design, methods, and baseline results. Contr Clin Trial 5(4):382–437, DOI 10.1016/S0197-2456(84)80017-3
Birkett M, Day S (1994) Internal pilot studies for estimating sample size. Stat Med 13(23–24):2455–2463, DOI 10.1002/sim.4780132309
Boyd S. and Vandenberghe L. (2004), “Convex Optimization”, Cambridge University Press, New York.
Brensike JF, Kelsey SF, Passamani ER, Fisher MR, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW, Moriarty DJ, Myrianthopoulos MB, Detre KM, Epstein SE, Levy RI (1982) National heart lung and blood institute type ii coronary intervention study: design, methods and baseline characteristics. Contr Clin Trial 3(2):91–111, DOI 10.1016/0197-2456(82)90038-1
Breslow NE, Clayton DG (1993) Approximate inference in generalized linear mixed models. J Am Statist Assoc 88(421):9–25
Bretz F, Schmidli H, König F, Racine A, Maurer W (2006) Confirmatory seamless phase II/III clinical trials with hypothesis selection at interim: general concepts. Biomet J 4:623–634, DOI 10.1002/bimj.200510232
Brookmeyer R, Crowley J (1982) A confidence interval for the median survival time. Biometrics 38:29–41
Burman CF, Sonesson C (2006) Are flexible designs sound? Biometrics 62(3):664–669, DOI 10.1111/j.1541-0420.2006.00626.x
Chan HP, Lai TL (2000) Asymptotic approximations for error probabilities of sequential or fixed sample size tests in exponential families. Ann Statist 28(6):1638–1669
Chang M (2007) Adaptive design theory and implementation using SAS and R. Chapman & Hall/CRC, Boca Raton
Chen RT, Davis RL, Rhodes PH (2005) Special methodological issues in pharmacoepidemiology studies of vaccine safety. In: Strom B (ed) Pharmacoepidemiology, 4th edn. Wiley, New York, pp 455–486
Chernoff H (1961) Sequential tests for the mean of a normal distribution. In: Proceedings of the 4th Berkeley symposium on mathematical statistics and probability, vol I, University of California Press, Berkeley, California, pp 79–91
Chernoff H (1965) Sequential tests for the mean of a normal distribution III (small t). Ann Math Statist 36:28–54
Chernoff H (1972) Sequential analysis and optimal design. Society for Industrial and Applied Mathematics, Philadelphia
Choi S, Smith P, Becker D (1985) Early decision in clinical trials when the treatment differences are small: experience of a controlled trial in head trauma. Contr Clin Trial 6(4):280–288, DOI 10.1016/0197-2456(85)90104-7
Chow SC, Chang M (2006) Adaptive design methods in clinical trials. Chapman & Hall/CRC, Boca Raton
Chuang CS, Lai TL (1998) Resampling methods for confidence intervals in group sequential trials. Biometrika 85(2):317–332
Chuang CS, Lai TL (2000) Hybrid resampling methods for confidence intervals. Statist Sinica 10(1):1–50, with discussion and rejoinder by the authors
Cook A, Tiwari R, Wellman R, Heckbert S, Li L, Heagerty P, Marsh T, Nelson J (2012) Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the mini-sentinel pilot. Pharmacoepidemiol Drug Safety 21:72–81
Cox DR (1972) Regression models and life-tables. J Roy Statist Soc Ser B 34:187–220, with discussion and a reply by the author
Cox DR (1975) Partial likelihood. Biometrika 62(2):269–276
Cui L, Hung HMJ, Wang SJ (1999) Modification of sample size in group sequential clinical trials. Biometrics 55(3):853–857
Dantzig GB (1940) On the non-existence of tests of “student’s” hypothesis having power functions independent of σ. Ann Math Statist 11:186–192
Davidian M, Giltinan DM (1995) Nonlinear models for repeated measurement data. Monographs on statistics & applied probability. Chapman and Hall/CRC, Boca Raton
Davis R, Kolczak M, Lewis E, Nordin J, Goodman M, Shay D, Platt R, Black S, Shinefield H, Chen R (2005) Active surveillance of vaccine safety – a system to detect early signs of adverse events. Epidemiology 16(3):336–341, DOI 10.1097/01.ede.0000155506.05636.a4
Denne JS (2001) Sample size recalculation using conditional power. Stat Med 20(17–18):2645–2660, DOI 10.1002/sim.734
Denne JS, Jennison C (1999) Estimating the sample size for a t-test using an internal pilot. Stat Med 18(13):1575–1585
Denne JS, Jennison C (2000) A group sequential t-test with updating of sample sizes. Biometrika 87(1):125–134, DOI 10.1093/biomet/87.1.125
Dixon WJ, Mood AM (1948) A method for obtaining and analyzing sensitivity data. J Am Statist Assoc 43(241):109–126
Durham SD, Flournoy N (1994) Random walks for quantile estimation. In: Statistical decision theory and related topics, V (West Lafayette, IN, 1992). Springer, New York, pp 467–476
Dvoretzky A, Kiefer J, Wolfowitz J (1953) Sequential decision problems for processes with continuous time parameter. Ann Math Statist 24:403–415
Eales JD, Jennison C (1992) An improved method for deriving optimal one-sided group sequential tests. Biometrika 79(1):13–24
Eales JD, Jennison C (1995) Optimal two-sided group sequential tests. Sequent Anal 14(4):273–286
Efron B (1987) Better bootstrap confidence intervals. J Am Statist Assoc 82(397):171–200, with comments and a rejoinder by the author
Eisenhauer EA, O’Dwyer PJ, Christian M, Humphrey JS (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684
Elfving G (1952) Optimum allocation in linear regression theory. Ann Math Statist 23:255–262
Ellenberg SS, Foulkes MA, Midthun K, Goldenthal KL (2005) Evaluating the safety of new vaccines: summary of a workshop. Am J Public Health 95(5):800–807, DOI 10.2105/AJPH.2004.039438
Emerson SS, Fleming TR (1989) Symmetric group sequential test designs. Biometrics 45(3):905–923
Emerson SS, Fleming TR (1990) Parameter estimation following group sequential hypothesis testing. Biometrika 77(4):875–892, DOI 10.1093/biomet/77.4.875
Facey KM (1992) A sequential procedure for a phase II efficacy trial in hypercholesterolemia. Contr Clin Trial 13(2):122–133, DOI 10.1016/0197-2456(92)90018-U
Fan J (1991) On the optimal rates of convergence for nonparametric deconvolution problems. Ann Statist 19(3):1257–1272, DOI 10.1214/aos/1176348248
Fedorov VV (1972) Theory of optimal experiments. In: Studden WJ, Klimko EM (eds) Probability and mathematical statistics, vol 12. Academic, New York, translated from the Russian
Fisher LD (1998) Self-designing clinical trials. Stat Med 17(14):1551–1562
Gehan EA (1965) A generalized wilcoxon test for comparing arbitrarily singly censored samples. Biometrika 52:203–223
Gould AL, Shih WJ (1992) Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Commun Statist A – Theor Method 21(10):2833–2853, DOI 10.1080/03610929208830947
Greene SK, Kulldorff M, Yin R, Yih WK, Lieu TA, Weintraub ES, Lee GM (2011) Near real-time vaccine safety surveillance with partially accrued data. Pharmacoepidemiol Drug Safety 20:583–590
Gross ST, Lai TL (1996) Bootstrap methods for truncated and censored data. Statist Sinica 6(3):509–530
Gu M, Lai TL (1991) Weak convergence of time-sequential censored rank statistics with applications to sequential testing in clinical trials. Ann Statist 19(3):1403–1433
Gu M, Lai TL (1998) Repeated significance testing with censored rank statistics in interim analysis of clinical trials. Statist Sinica 8(2):411–428
Gu M, Lai TL (1999) Determination of power and sample size in the design of clinical trials with failure-time endpoints and interim analyses. Contr Clin Trials 20(5):423–438, DOI 10.1016/S0197-2456(99)00021-5
Gu M, Lai TL, Lan KKG (1991) Rank tests based on censored data and their sequential analogues. Am J Math Manag Sci 11(1–2):147–176
Haines LM, Perevozskaya I, Rosenberger WF (2003) Bayesian optimal designs for phase I clinical trials. Biometrics 59(3):591–600, DOI 10.1111/1541-0420.00069
Hall P (1992) The Bootstrap and edgeworth expansion. Springer, New York
Hall WJ, Yakir B (2003) Inference about a secondary process following a sequential trial. Biometrika 90(3):597–611, DOI 10.1093/biomet/90.3.597
Han J, Lai TL, Spivakovsky V (2006) Approximate policy optimization and adaptive control in regression models. Comput Econ 27:433–452
Harrington DP, Fleming TR (1982) A class of rank test procedures for censored survival data. Biometrika 69(3):553–566, DOI 10.1093/biomet/69.3.553
Haybittle J (1971) Repeated assessment of results in clinical trials of cancer treatment. Brit J Radiol 44(526):793–&
He P, Lai TL, Liao OY (2012) Futility stopping in clinical trials. Stat Interface To appear
Herson J (1979) Predictive probability early termination plans for phase II clinical trials. Biometrics 35(4):775–783, DOI 10.2307/2530109
Herson J, Wittes JT (1993) The use of interim analysis in sample size adjustment. Drug Inf J 27:753–760
Heyse JF, Kuter BJ, Dallas MJ, Heaton P, REST Study Team (2008) Evaluating the safety of a rotavirus vaccine: the REST of the story. Clin Trials 5(2):131–139, DOI 10.1177/1740774508090507
Hoeffding W (1960) Lower bounds for the expected sample size and the average risk of a sequential procedure. Ann Math Statist 31:352–368
Huang X, Ning J, Li Y, Estey E, Issa JP, Berry DA (2009) Using short-term response information to facilitate adaptive randomization for survival clinical trials. Stat Med 28(12):1680–1689, DOI 10.1002/sim.3578
Inoue LYT, Thall PF, Berry DA (2002) Seamlessly expanding a randomized Phase II trial to Phase III. Biometrics 58:823–831
Jennison C, Turnbull BW (1990) Statistical approaches to interim monitoring of medical trials: a review and commentary. Statist Sci 5(3):299–317
Jennison C, Turnbull BW (2000) Group sequential methods with applications to clinical trials. Chapman & Hall/CRC, Boca Raton
Jennison C, Turnbull BW (2003) Mid-course sample size modification in clinical trials based on the observed treatment effect. Stat Med 22(6):971–993, DOI 10.1002/sim.1457
Jennison C, Turnbull BW (2006a) Adaptive and nonadaptive group sequential tests. Biometrika 93(1):1–21, DOI 10.1093/biomet/93.1.1
Jennison C, Turnbull BW (2006b) Efficient group sequential designs when there are several effect sizes under consideration. Stat Med 25(6):917–932, DOI 10.1002/sim.2251
Johnson RA (1970) Asymptotic expansions associated with posterior distributions. Ann Math Statist 41:851–864
Julious S, Swank D (2005) Moving statistics beyond the individual clinical trial: applying decision science to optimize a clinical development plan. Pharmaceut Statist 4(1):37–46, DOI 10.1002/pst.149
Katzung BG (1995) Basic and clinical pharmacology, 6th edn. Prentice Hall, Englewood, Cliffs
Kiefer J (1974) General equivalence theory for optimum designs (approximate theory). Ann Statist 2:849–879
Kiefer J, Weiss L (1957) Some properties of generalized sequential probability ratio tests. Ann Math Statist 28:57–74
Kim K, DeMets DL (1987) Design and analysis of group sequential tests based on the type I error spending rate function. Biometrika 74(1):149–154
Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM (1994) A comparison of two phase I trial designs. Stat Med 13(18):1799–1806, DOI 10.1002/sim.4780131802
Kulldorff M, Davis R, Kolczak M, Lewis E, Lieu T, Platt R (2011) A maximized sequential probability ratio test for drug and vaccine safety surveillance. Sequent Anal 30(1):58–78
Lai TL (1973) Optimal stopping and sequential tests which minimize the maximum expected sample size. Ann Statist 1:659–673
Lai TL (1988) Nearly optimal sequential tests of composite hypotheses. Ann Statist 16(2):856–886
Lai TL (1995) Sequential changepoint detection in quality control and dynamical systems. J Roy Statist Soc Ser B 57(4):613–658, with discussion and a reply by the author
Lai TL (1997) On optimal stopping problems in sequential hypothesis testing. Statist Sinica 7(1):33–51
Lai TL (1998) Information bounds and quick detection of parameter changes in stochastic systems. IEEE Trans Inform Theory 44:2917–2929
Lai TL (2001) Sequential analysis: some classical problems and new challenges. Statist Sinica 11(2):303–408, with comments and a rejoinder by the author
Lai TL (2004) Likelihood ratio identities and their applications to sequential analysis. Sequent Anal 23(4):467–497
Lai TL, Li W (2006) Confidence intervals in group sequential trials with random group sizes and applications to survival analysis. Biometrika 93(3):641–654
Lai TL, Liao OY (2012) Efficient adaptive randomization and stopping rules in multi-arm clinical trials for testing a new treatment. Sequent Anal To appear
Lai TL, Robbins H (1979) Adaptive design and stochastic approximation. Ann Statist 7(6):1196–1221
Lai TL, Shih MC (2003a) A hybrid estimator in nonlinear and generalised linear mixed effects models. Biometrika 90(4):859–879
Lai TL, Shih MC (2003b) Nonparametric estimation in nonlinear mixed effects models. Biometrika 90(1):1–13
Lai TL, Shih MC (2004) Power, sample size and adaptation considerations in the design of group sequential clinical trials. Biometrika 91(3):507–528
Lai TL, Su Z (2006) Confidence intervals for survival quantiles in the cox regression model. Lifetime Data Anal 12:407–419
Lai TL, Wang JQ (1994) Asymptotic expansions for the distributions of stopped random walks and first passage times. Ann Probab 22(4):1957–1992
Lai TL, Xing H (2010) Sequential change-point detection when the pre- and post-change parameters are unknown. Sequent Anal 29:162–175
Lai TL, Zhang L (1994) A modification of schwarz’s sequential likelihood ratio tests in multivariate sequential analysis. Sequent Anal 13(2):79–96
Lai T, Su Z, Chuang C (2006a) Bias correction and confidence intervals following sequential tests. In: Lecture Notes-Monograph Series, JSTOR, pp 44–57
Lai TL, Shih MC, Wong S (2006b) A new approach to modeling covariate effects and individualization in population pharmacokinetics-pharmacodynamics. J Pharmacok Pharmacodynam 33:49–74, DOI 10.1007/s10928-005-9000-2
Lai TL, Shih MC, Zhu G (2006c) Modified Haybittle-Peto group sequential designs for testing superiority and non-inferiority hypotheses in clinical trials. Stat Med 25(7):1149–1167
Lai TL, Shih MC, Su Z (2009) Tests and confidence intervals for secondary endpoints in sequential clinical trials. Biometrika 96:903–915, DOI 10.1093/biomet/asp063
Lai TL, Lavori PW, Shih MC (2012a) Sequential design of phase II–III cancer trials. Stat Med 31(18):1944–1960, DOI 10.1002/sim.5346
Lai TL, Lavori PW, Shih MC, Sikic BI (2012b) Clinical trial designs for testing biomarker-based personalized therapies. Clin Trials 9(2):141–154, DOI 10.1177/1740774512437252
Lai TL, Liao OY, Zhu G (2012c) Adaptation in clinical development plans and adaptive clinical trial designs. Stat Interface To appear
Lan KKG, DeMets DL (1983) Discrete sequential boundaries for clinical trials. Biometrika 70(3):659–663
Lan KKG, Wittes J (1988) The B-value: a tool for monitoring data. Biometrics 44(2):579–585, DOI 10.2307/2531870
Lan KKG, Simon R, Halperin M (1982) Stochastically curtailed tests in long-term clinical trials. Comm Statist C—Sequent Anal 1(3):207–219
Lehmacher W, Wassmer G (1999) Adaptive sample size calculations in group sequential trials. Biometrics 55(4):1286–1290, DOI 10.1111/j.0006-341X.1999.01286.x
Li G, Shih WJ (2002) A sample size adjustment procedure for clinical trials based on conditional power. Biostatistics 3(2):277–287, DOI 10.1093/biostatistics/3.2.277
Li L (2009) A conditional sequential sampling procedure for drug safety surveillance. Stat Med 28(25):3124–3138, DOI 10.1002/sim.3689
Li L, Kulldorff M (2010) A conditional maximized sequential probability ratio test for pharmacovigilance. Stat Med 29(2):284–295
Lieu TA, Kulldorfif M, Davis RL, Lewis EM, Weintraub E, Yih K, Yin R, Brown JS, Platt R (2007) Real-time vaccine safety surveillance for the early detection of adverse events. Med Care 45(10, Suppl. 2):S89–S95
Lindstrom MJ, Bates DM (1990) Nonlinear mixed effects models for repeated measures data. Biometrics 46(3):673–687, DOI 10.2307/2532087
Liu A, Hall WJ (1999) Unbiased estimation following a group sequential test. Biometrika 86(1):71–78, DOI 10.1093/biomet/86.1.71
Liu A, Tan M, Boyett JM, Xiong XP (2000) Testing secondary hypotheses following sequential clinical trials. Biometrics 56(2):640–644
Liu Q, Pierce DA (1994) A note on Gauss-Hermite quadrature. Biometrika 81(3):624–629, DOI 10.1093/biomet/81.3.624
Lorden G (1971) Procedures for reacting to a change in distribution. Ann Math Statist 42:1897–1908
Lorden G (1976) 2-SPRT’s and the modified Kiefer-Weiss problem of minimizing an expected sample size. Ann Statist 4(2):281–291
Lorden G (1983) Asymptotic efficiency of three-stage hypothesis tests. Ann Statist 11(1):129–140
Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherap Rep 50(3):163–170
Müller HG, Wang JL (1994) Hazard rate estimation under random censoring with varying kernels and bandwidths. Biometrics 50:61–76
Murphy T, Gargiullo P, Massoudi M, Nelson D, Jumaan A, Okoro C, Zanardi L, Setia S, Fair E, LeBaron C, Schwartz B, Wharton M, Livingood J (2001) Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344(8):564–572
Murphy T, Smith P, Gargiullo P, Schwartz B (2003) The first rotavirus vaccine and intussusception: epidemiological studies and policy decisions. J Infec Dis 187(8):1309–1313
Nelson J, Cook A, Yu O, Dominguez C, Zhao S, Greene S, Fireman B, Jacobsen S, Weintraub E, Jackson L (2012) Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. Pharmacoepidemiol Drug Safety 21:62–71
Newlands E, Blackledge G, Slack J, Rustin G, Smith D, Stuart N, Quarterman C, Hoffman R, Stevens M, Brampton M, Gibson A (1992) Antitumor imidazotetrazines.26. phase I trial of temozolomide (ccrg-81045, m-and-b 39831, nsc-362856). Br J Cancer 65(2):287–291, DOI 10.1038/bjc.1992.57
Nguyen M, Ball R, Midthun K, Lieu T (2012) The food and drug administration’s post-licensure rapid immunization safety monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiol Drug Safety 21:291–297
O’Brien PC, Fleming TR (1979) Multiple testing procedure for clinical trials. Biometrics 35(3):549–556
O’Quigley J (2002) Continual reassessment designs with early termination. Biostatistics 3(1):87–99, DOI 10.1093/biostatistics/3.1.87
O’Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46(1):33–48, DOI 10.2307/2531628
Page ES (1954) Continuous inspection schemes. Biometrika 41:100–115
Pampallona S, Tsiatis AA (1994) Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. J Statist Plan Infer 42(1–2):19–35
Pepe MS, Anderson GL (1992) Two-stage experimental designs: early stopping with a negative result. J Roy Statist Soc Ser C 41(1):181–190, DOI 10.2307/2347627
Peto R, Peto J (1972) Asymptotically efficient rank invariant test procedures. J Roy Statist Soc Ser A 135(2):185–207
Peto R, Pike M, Armitage P, Breslow N, Cox D, Howard S, Mantel N, McPherson K, Peto J, Smith P (1976) Design and analysis of randomized clinical trials requiring prolonged observation of each patient 1. Introduction and design. Br J Cancer 34(6):585–612
Pinheiro JC, Bates DM (1995) Approximations to the log-likelihood function in the nonlinear mixed-effects model. J Comput Graph Stat 4(1):12–35
Platt R, Carnahan R, Brown J, Chrischilles E, Curtis L, Hennessy S, Nelson J, Racoosin J, Robb M, Schneeweiss S et al (2012) The us food and drug administration’s mini-sentinel program: status and direction. Pharmacoepidemiol Drug Safety 21:1–8
Pocock SJ (1977) Group sequential methods in the design and analysis of clinical trials. Biometrika 64(2):191–199
Pollak M (1985) Optimal detection of a change in distribution. Ann Statist 13:206–227
Posch M, Bauer P (1999) Adaptive two stage designs and the conditional error function. Biom J 41(6):689–696
Prentice RL (1978) Linear rank tests with right censored data. Biometrika 65(1):167–179, DOI 10.1093/biomet/65.1.167
Press NH, Flannery BP, Teukolsky SA, Vitterling WT (1992) Numerical recipes in C: the art of scientific computing, 2nd edn. Cambridge University Press, Cambridge
Proschan MA, Hunsberger SA (1995) Designed extension of studies based on conditional power. Biometrics 51(4):1315–1324, DOI 10.2307/2533262
Proschan MA, Lan KG, Wittes JT (2006) Statistical monitoring of clinical trials: a unified approach. Springer, New York, DOI 10.1007/978-0-387-44970-8
Reiner E, Paoletti X, O’Quigley J (1999) Operating characteristics of the standard phase I clinical trial design. Comput Stat Data Anal 30(3):303–315, DOI 10.1016/S0167-9473(98)00095-4
Robbins H, Monro S (1951) A stochastic approximation method. Ann Math Statist 22:400–407
Roberts SW (1966) A comparison of some control chart procedures. Technometrics 8:411–430
Rosner GL, Tsiatis AA (1988) Exact confidence-intervals following a group sequential trial – a comparison of methods. Biometrika 75(4):723–729
Rowland M, Tozer TN (1989) Clinical pharmacokinetics: concepts and applications, 2nd edn. Lea and Febiger Phildelphia
Rubinstein L, Crowley J, Ivy P, LeBlanc M, Sargent D (2009) Randomized phase II designs. Clin Cancer Res 15:1883–1890, DOI 10.1158/1078-0432.CCR-08-2031
Sacks J (1958) Asymptotic distribution of stochastic approximation procedures. Ann Math Statist 29:373–405
Scharfstein DO, Tsiatis AA (1998) The use of simulation and bootstrap in information-based group sequential studies. Stat Med 17(1):75–87
Scharfstein DO, Tsiatis AA, Robins JM (1997) Semiparametric efficiency and its implication on the design and analysis of group-sequential studies. J Am Statist Assoc 92(440):1342–1350, DOI 10.2307/2965404
Schmitz N (1993) Optimal sequentially planned decision procedures. Lecture notes in statistics, vol 79. Springer, New York
Schwarz G (1962) Asymptotic shapes of Bayes sequential testing regions. Ann Math Statist 33:224–236
Shen Y, Fisher L (1999) Statistical inference for self-designing clinical trials with a one-sided hypothesis. Biometrics 55(1):190–197, DOI 10.1111/j.0006-341X.1999.00190.x
Shewhart WA (1931) Economic control of manufactured products. Van Nostrand Reinhold, New York
Shih MC, Lai TL, Heyse JF, Chen J (2010) Sequential generalized likelihood ratio tests for vaccine safety evaluation. Stat Med 29(26):2698–2708, DOI 10.1002/sim.4036
Shih WJ (2001) Sample size re-estimation: Journey for a decade. Stat Med 20(4):515–518, DOI 10.1002/sim.532
Siegmund D (1978) Estimation following sequential tests. Biometrika 65(2):341–349, DOI 10.2307/2335213
Siegmund D (1985) Sequential analysis. Springer, New York
Siegmund D, Venkatraman ES (1995) Using the generalized likelihood ratio statistics for sequential detection of a change-point. Ann Statist 23:255–271
Silvey SD (1980) Optimal design. Monographs on applied probability and statistics. Chapman & Hall, London
Simon R (1989) Designs for efficient clinical trials. Oncology 3(7):43–53 with discussion
Simon R (1989) Optimal 2-stage designs for phase II clinical trials. Contr Clin Trial 10(1):1–10, DOI 10.1016/0197-2456(89)90015-9
Slud E, Wei LJ (1982) Two-sample repeated significance tests based on the modified Wilcoxon statistic. J Am Statist Assoc 77(380):862–868
Sonesson C, Bock D (2003) A review and discussion of prospective statistical surveillance in public health. J Roy Statist Soc Ser A 166(1):5–21, DOI 10.1111/1467-985X.00256
Spiegelhalter D, Freedman L, Blackburn P (1986) Monitoring clinical trials: Conditional or predictive power? Contr Clin Trial 7(1):8–17, DOI 10.1016/0197-2456(86)90003-6
Stein C (1945) A two-sample test for a linear hypothesis whose power is independent of the variance. Ann Math Statist 16:243–258
Storer B (1989) Design and analysis of phase I clinical trials. Biometrics 45(3):925–937, DOI 10.2307/2531693
Susarla V, Van Ryzin J (1976) Nonparametric Bayesian estimation of survival curves from incomplete observations. J Am Statist Assoc 71(356):897–902
Todd S, Whitehead J (1996) Point and interval estimation following a sequential clinical trial. Biometrika 83(2):453–461
Tsiatis AA (1981) The asymptotic joint distribution of the efficient scores test for the proportional hazards model calculated over time. Biometrika 68(1):311–315, DOI 10.1093/biomet/68.1.311
Tsiatis AA, Mehta C (2003) On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 90(2):367–378, DOI 10.1093/biomet/90.2.367
Vickers AJ, Ballen V, Scher HI (2007) Setting the bar in phase II trials: the use of historical data for determining “go/no go” decision for definitive phase III testing. Clin Cancer Res 13(3):972–976, DOI 10.1158/1078-0432.CCR-06-0909
Von Hoff DD, Turner J (1991) Response rates, duration of response, and dose-response effects in phase I studies of antineoplastics. Invest New Drugs 9(1):115–122
Vonesh EF (1996) A note on the use of Laplace’s approximation for nonlinear mixed-effects models. Biometrika 83(2):447–452, DOI 10.1093/biomet/83.2.447
Wald A (1945) Sequential tests of statistical hypotheses. Ann Math Statist 16:117–186
Wald A, Wolfowitz J (1948) Optimum character of the sequential probability ratio test. Ann Math Statist 19:326–339
Wallis WA (1980) The statistical research group, 1942–1945. J Am Statist Assoc 75(370):320–335, with comments by F.J. Anscombe and William H. Kruskal and a reply by the author
Wang S, Hung H, Tsong Y, Cui L (2001) Group sequential test strategies for superiority and non-inferiority hypotheses in active controlled clinical trials. Stat Med 20(13):1903–1912
Wang SK, Tsiatis AA (1987) Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 43(1):193–199
Wassmer G, Vandemeulebroecke M (2006) A brief review on software developments for group sequential and adaptive designs. Biom J 48(4):732–737, DOI 10.1002/bimj.200510233
Whitehead J (1986) Supplementary analysis at the conclusion of a sequential clinical trial. Biometrics 42(3):461–471
Whitehead J (1992) The design and analysis of sequential clinical trials, 2nd edn. Wiley, New York
Whitehead J, Stratton I (1983) Group sequential clinical trials with triangular continuation regions. Biometrics 39(1):227–236
Whitehead J, Todd S, Hall WJ (2000) Confidence intervals for secondary parameters following a sequential test. J Roy Statist Soc Ser B 62(4):731–745, DOI 10.1111/1467-9868.00260
Whitehead J, Whitehead A, Todd S, Bolland K, Sooriyarachchi M (2001) Mid-trial design reviews for sequential clinical trials. Stat Med 20(2):165–176
Willsky AS, Jones HG (1976) A generalized likelihood ratio approach to detection and estimation of jumps in linear systems. IEEE Trans Automat Contr 21:108–112
Wilson EB, Worcester J (1943) The determination of L.D.50 and its sampling error in bio-assay. Proc Nat Acad Sci U S A 29(2):79–85
Wittes J, Brittain E (1990) The role of internal pilot: studies in increasing the efficiency of clinical trials. Stat Med 9(1–2):65–72, DOI 10.1002/sim.4780090113
Wolfinger R (1993) Laplace’s approximation for nonlinear mixed models. Biometrika 80(4):791–795, DOI 10.1093/biomet/80.4.791
Wolfinger R, O’Connell M (1993) Generalized linear mixed models: a pseudo-likelihood approach. J Stat Comput Sim 48(3–4):233–243, DOI 10.1080/00949659308811554
Woodroofe M (1986) Very weak expansions for sequential confidence levels. Ann Statist 14(3):1049–1067, DOI 10.1214/aos/1176350049
Woodroofe M (1992) Estimation after sequential testing: a simple approach for a truncated sequential probability ratio test. Biometrika 79(2):347–353, DOI 10.1093/biomet/79.2.347
Wu CFJ (1985) Efficient sequential designs with binary data. J Am Statist Assoc 80(392):974–984
Yafune A, Takebe M, Ogata H (1998) A use of Monte Carlo integration for population pharmacokinetics with multivariate population distribution. J Pharmacok Biopharm 26(1):103–123, DOI 10.1023/A:1023280909207
Yin G, Yuan Y (2009) Bayesian model averaging continual reassessment method in phase I clinical trials. J Am Statist Assoc 104(487):954–968, DOI 10.1198/jasa.2009.ap08425
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bartroff, J., Lai, T.L., Shih, MC. (2013). Time-Sequential Design of Clinical Trials with Failure-Time Endpoints. In: Sequential Experimentation in Clinical Trials. Springer Series in Statistics, vol 298. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6114-2_6
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6114-2_6
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6113-5
Online ISBN: 978-1-4614-6114-2
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)